Thursday, 02 February 2023
New research from the University of Nottingham demonstrates that online behaviour therapy for children with tics, which is supported by therapists, is both effective, safe and could greatly increase the number of children who are helped.
The Online Remote Behavioural Intervention for Tics (ORBIT) trial was led by Professor Chris Hollis, Professor of Child & Adolescent Psychiatry at the University of Nottingham, Director of MindTech, and Consultant in Developmental Neuropsychiatry with Nottinghamshire Healthcare NHS Trust.
Funded by the National Institute for Health and Care Research (NIHR), the research is a collaboration with the Institute of Mental Health, NIHR MindTech, Nottinghamshire Healthcare NHS Foundation Trust, Great Ormond Street Hospital, University of Nottingham, University College London (Priment) and the Karolinska Institutet (Sweden). Researchers also worked closely with the charity Tourettes Action.
The ORBIT trial compared an online behavioural therapy (called exposure and response prevention) with an online psychoeducation programme in 9-17 year olds with Tourette Syndrome or chronic tic disorder. This research builds on the study’s previous findings that online treatment is a safe and effective intervention, improving access to treatment for this under-served group of young people. The study also found online delivery of treatment was cost-effective.
The results from this trial are very promising, enabling individuals to access evidence-based treatment to help them better manage and control their tics online. It could potentially improve the lives of so many people.
Around 70,000 children and young people in England have Tourette Syndrome, the condition most commonly associated with chronic tics. Tic disorders can cause distress in a young person’s school and social life. Despite the profound impact tics have on the lives of those who experience them, less than 1 in 5 people living with tics have access to behavioural therapy.
Dr Charlotte Hall, Principal Research Fellow at the University of Nottingham and ORBIT Trial Manager, said: “These findings are exciting. They are the first to show the long-term benefits of online delivered therapy for tics. We hear a lot from clinicians who want to be able to offer tic therapy but don’t have the skills, money, or resources to offer it. Likewise, we know families who are desperate to access therapy.
“This new online therapy is not yet available on the NHS but, given the importance of our findings in being able to bridge this gap in service provision, we are now working actively with various stakeholders, including the NHS, to show how ORBIT can be implemented as part of routine NHS care.”
Emma McNally, CEO Tourette’s Action, commented: “It’s shocking that a condition so prevalent has such inadequate access to appropriate care. More than 300,000 people in the UK are known to have Tourette’s, but that number is probably much, much higher. Many people report that they are unable to access treatment locally, more often than not, they gain a diagnosis and then are discharged with no access to treatment.”
“I’ve heard from parents who talk of holding their child in their arms in tears, unable to stop motor tics that are so repetitive they become physically painful. Adults who describe muscle spasms so intense and so uncontrollable that they are in extreme pain and yet are unable to stop the tics. The results from this trial are very promising, enabling individuals to access evidence-based treatment to help them better manage and control their tics online. This will be extremely beneficial to individuals who currently have no services local to them. It could potentially improve the lives of so many people.”
The research has been published in the Journal of Child Psychology and Psychiatry.
Story credits
For further information, please contact Professor Chris Hollis.
Adam Mallaby - Media Relations Manager for the Faculty of Medicine and Health Sciences (Maternity Cover)
Email: adam.mallaby@nottingham.ac.uk
Phone: 0115 748 5719
Location:
Notes to editors:
About the University of Nottingham
Ranked 32 in Europe and 16th in the UK by the QS World University Rankings: Europe 2024, the University of Nottingham is a founding member of the Russell Group of research-intensive universities. Studying at the University of Nottingham is a life-changing experience, and we pride ourselves on unlocking the potential of our students. We have a pioneering spirit, expressed in the vision of our founder Sir Jesse Boot, which has seen us lead the way in establishing campuses in China and Malaysia - part of a globally connected network of education, research and industrial engagement.
Nottingham was crowned Sports University of the Year by The Times and Sunday Times Good University Guide 2024 – the third time it has been given the honour since 2018 – and by the Daily Mail University Guide 2024.
The university is among the best universities in the UK for the strength of our research, positioned seventh for research power in the UK according to REF 2021. The birthplace of discoveries such as MRI and ibuprofen, our innovations transform lives and tackle global problems such as sustainable food supplies, ending modern slavery, developing greener transport, and reducing reliance on fossil fuels.
The university is a major employer and industry partner - locally and globally - and our graduates are the second most targeted by the UK's top employers, according to The Graduate Market in 2022 report by High Fliers Research.
We lead the Universities for Nottingham initiative, in partnership with Nottingham Trent University, a pioneering collaboration between the city’s two world-class institutions to improve levels of prosperity, opportunity, sustainability, health and wellbeing for residents in the city and region we are proud to call home.
More news…